Can a new drug tackle Hard-to-Treat gynecologic cancers?

NCT ID NCT07755436

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This early-stage trial is testing an investigational drug called ARR-002 in adults with advanced or metastatic ovarian or endometrial cancer, including cases that have stopped responding to platinum-based chemotherapy. The main goals are to assess the drug's safety, tolerability, and how the body processes it, while also looking for early signs that it can shrink tumors. Participants must have measurable disease and provide a tumor sample for testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ARR-002, an investigational drug
What this could lead to
If successful, ARR-002 could offer a new treatment option for people with advanced ovarian or endometrial cancer that has stopped responding to standard therapy.
What could go wrong
This is an early-phase trial focused on safety and dosing, so it is not yet known if ARR-002 will effectively shrink tumors or improve outcomes. Side effects and limited benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NEXT Oncology

    RECRUITING

    Irving, Texas, 75039, United States

  • NEXT Oncology

    RECRUITING

    Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.